These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 19481572)

  • 1. Emerging role of glutamate in the pathophysiology of major depressive disorder.
    Hashimoto K
    Brain Res Rev; 2009 Oct; 61(2):105-23. PubMed ID: 19481572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine and other potential glutamate antidepressants.
    Dutta A; McKie S; Deakin JFW
    Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of NMDA receptors in the treatment of major depression.
    Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
    Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
    Miller OH; Moran JT; Hall BJ
    Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamatergic NMDA Receptor as Therapeutic Target for Depression.
    Réus GZ; Abelaira HM; Tuon T; Titus SE; Ignácio ZM; Rodrigues AL; Quevedo J
    Adv Protein Chem Struct Biol; 2016; 103():169-202. PubMed ID: 26920690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.
    Ren Z; Pribiag H; Jefferson SJ; Shorey M; Fuchs T; Stellwagen D; Luscher B
    Biol Psychiatry; 2016 Sep; 80(6):457-468. PubMed ID: 27062563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the role of metabotropic glutamate receptors in the mechanisms of action of antidepressants.
    Pałucha A; Pilc A
    Pol J Pharmacol; 2002; 54(6):581-6. PubMed ID: 12866712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex differences in glutamate receptor gene expression in major depression and suicide.
    Gray AL; Hyde TM; Deep-Soboslay A; Kleinman JE; Sodhi MS
    Mol Psychiatry; 2015 Sep; 20(9):1057-68. PubMed ID: 26169973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamate-based antidepressants: 20 years on.
    Skolnick P; Popik P; Trullas R
    Trends Pharmacol Sci; 2009 Nov; 30(11):563-9. PubMed ID: 19837463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression.
    Chourbaji S; Vogt MA; Fumagalli F; Sohr R; Frasca A; Brandwein C; Hörtnagl H; Riva MA; Sprengel R; Gass P
    FASEB J; 2008 Sep; 22(9):3129-34. PubMed ID: 18492725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: implications for schizophrenia.
    Zavitsanou K; Nguyen V; Newell K; Ballantyne P; Huang XF
    J Chem Neuroanat; 2008 Oct; 36(2):71-6. PubMed ID: 18640263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to the pharmacological management of major depressive disorder.
    Witkin JM; Li X
    Adv Pharmacol; 2009; 57():347-79. PubMed ID: 20230766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.
    Mathews DC; Henter ID; Zarate CA
    Drugs; 2012 Jul; 72(10):1313-33. PubMed ID: 22731961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrastructural analysis of the glutamatergic system in the outer plexiform layer of zebrafish retina.
    Klooster J; Yazulla S; Kamermans M
    J Chem Neuroanat; 2009 Jul; 37(4):254-65. PubMed ID: 19481010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of NMDA receptors in the pathophysiology and treatment of mood disorders.
    Ghasemi M; Phillips C; Trillo L; De Miguel Z; Das D; Salehi A
    Neurosci Biobehav Rev; 2014 Nov; 47():336-58. PubMed ID: 25218759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
    Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
    Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data].
    Paslakis G; Gass P; Deuschle M
    Fortschr Neurol Psychiatr; 2011 Apr; 79(4):204-12. PubMed ID: 21117011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.